Arch Therapeutics Inc (ARTH) News

Arch Therapeutics Inc (ARTH): $0.04

0.00 (-1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ARTH News Items

ARTH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ARTH News From Around the Web

Below are the latest news stories about Arch Therapeutics Inc that investors may wish to consider to help them evaluate ARTH as an investment opportunity.

Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

Medical Industry Veteran with Proven Track Record to Drive Commercialization Effort FRAMINGHAM, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that Dan Yrigoyen has joined the organization as Vice President of Sales. Mr. Yrigoyen will lead the Company’s national commercialization effort with a focus on revenue generation and channel development. Mr. Yr

Yahoo | July 12, 2021

Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

FRAMINGHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will present at the upcoming Ladenburg Thalmann 2021 Healthcare Conference, which shall be held July 13-14, 2021. Chief Executive Officer, Terry Norchi, MD, is scheduled to provide a corporate update and, along with Chief Financial Officer, Mike Abrams, participate in a subsequent quest

Yahoo | July 7, 2021

Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021. You m

Yahoo | June 2, 2021

Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer

Company Prepares for Next Stage of GrowthFRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the Company’s succession plan, Mr. Abrams joins Arch’s financial team today, one week before assuming the role currently held by the Company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021. Mr. Abrams has over 25 years of experience as a Chief Financial Officer...

Yahoo | May 3, 2021

Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021

Management to provide corporate update on Dermal Sciences and BioSurgeryFRAMINGHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devices, announced today that it will be presenting at the H.C. Wainwright Global Life Sciences Conference, which will be held March 9-10, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast and be available for meetings. The webcast will be available on-demand starting at 7:00 A.M. EST, Tuesday, March 9, 2021. You may access the live webcast by clicking here: webcast. Attendees may find conference information and registe...

Yahoo | March 2, 2021

Arch Therapeutics Announces $6.9 Million Private Placement

FRAMINGHAM, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $6.9 million through the issuance of an aggregate 43,125,002 shares of its common stock and warrants to purchase up to an aggregate of 32,343,751 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement. The closing of the private placement is expected to occur on or about February 17, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is actin...

Yahoo | February 12, 2021

Arch Therapeutics to Present at the H.C. Wainwright BioConnect Conference, January 11 - 14, 2021

FRAMINGHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the H.C. Wainwright BioConnect Conference, which will be held January 11-14, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast, which will be available on-demand as of 6:00 AM ET, Monday, Jan. 11, 2021. You may access the live webcast here: https://journey.ct.events/view/69fcfc59-7ff6-41b6-bbe7-17285bda3d86.Conference attendees may request meetings with management here: https://hcwevents.com/bioconnect/.After the event, the presentation will be available here: https://ir...

Yahoo | January 5, 2021

Arch Therapeutics Announces Distribution Agreement with Buffalo Supply, Inc.

Partnership provides US government facilities access and product distribution supportFRAMINGHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it has entered into a distribution and sales administration agreement with Buffalo Supply, Inc. (“Buffalo Supply” or “BSI”) to be the exclusive distributor for products sold to United States government facilities worldwide. Buffalo Supply will place Arch products on their federal contracts and maintain compliance with Federal Acquisition Regulations (FARs), in addition to coordinating the processing of purchase orders and collection of payments for Arch products that are sold to Veterans Healthca...

Yahoo | January 4, 2021

Arch Therapeutics to Present at the 13th Annual LD Micro Main Event Conference

FRAMINGHAM, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announced today that it will be presenting at the 13th annual LD Micro Main Event investor conference. This investor conference will take place December 14-15, 2020, on the Sequire Virtual Events platform. Chief Executive Officer, Terrence W. Norchi, MD, is scheduled to present on Tuesday, December 15 at 11:40 AM ET. The Main Event will feature a new format, with companies presenting for approximately 10 minutes followed by questions from a panel of investors and analysts.You may register for the event here: https://ve.mysequire.com/.You may access the live webcast here: https://ve.mysequire.com/comp...

Yahoo | December 11, 2020

Arch Raises Approximately $1.1 Million with Convertible Note Issuance

Financing with long-term shareholders provides flexibility during product roll-outFRAMINGHAM, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel self-assembling wound care and biosurgical devices, announces that it has raised approximately $1.1M from long-term shareholders. As part of the capital raising, the Company has issued convertible notes (the “Notes”) to several accredited current investors for the aggregate principal amount of approximately $1.1 million. The Notes accrue simple interest on unpaid principal at a rate of ten percent per year. Features of the Notes allow for payment of principal plus accrued interest at any time up until maturity as well as conversion into common stock under certain conditi...

Yahoo | November 10, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6063 seconds.